By Billy Candra 
Deciding whether to initiate hormone therapy (HT) during the menopause transition, a pivotal life phase marking the cessation of a woman’s menstrual cycle, remains a subject of considerable debate within medical and public discourse. While hormone therapy, which involves replacing naturally diminishing hormones with synthetic medication, is widely recognized for its efficacy in alleviating bothersome menopausal symptoms such as hot flashes and night sweats, there has been persistent uncertainty regarding its long-term effects, particularly concerning cardiovascular health. This confusion has led to a fluctuating consensus among healthcare providers and patients alike, often characterized by a "pendulum swing" in recommendations over the past decades.
New Research Sheds Light on Cardiovascular Biomarkers
A recent study, spearheaded by Matthew Nudy, an assistant professor of medicine at the Penn State College of Medicine, suggests that long-term use of estrogen-based hormone therapies may offer beneficial effects on heart health. This multi-institutional investigation meticulously analyzed extensive data from hormone therapy clinical trials originally conducted as part of the landmark Women’s Health Initiative (WHI) – a comprehensive, long-term national study focused on menopausal women. The research team’s findings indicate that estrogen-based hormone therapy positively influenced various biomarkers associated with cardiovascular health over an extended period. Crucially, the study highlights a potential role for hormone therapy in significantly lowering levels of lipoprotein(a) [Lp(a)], a genetically determined risk factor strongly correlated with an elevated risk of heart attack and stroke.
The detailed findings of this significant research were formally published in the esteemed journal Obstetrics & Gynecology. Dr. Nudy emphasized that this study contributes substantially to the ongoing understanding of the intricate interplay between hormone therapy and cardiovascular well-being, providing valuable additional guidance for both patients navigating menopausal health decisions and the clinicians advising them. "The pendulum has been swinging back and forth as to whether hormone therapy is safe for menopausal women, especially from a cardiovascular disease perspective," Nudy stated, reflecting on the historical shifts in medical opinion. He added, "More recently, we’re recognizing that hormone therapy is safe in younger menopausal women within 10 years of menopause onset, who are generally healthy and who have no known cardiovascular disease." This statement underscores a growing consensus that timing and individual health profiles are critical determinants in assessing HT suitability.
Menopause and the Escalating Risk of Cardiovascular Disease
Beyond the well-known discomforts of hot flashes and night sweats, the profound hormonal shifts accompanying menopause usher in another critical physiological change: a markedly increased risk of cardiovascular disease (CVD). The natural decline in estrogen levels during this phase can precipitate a cascade of detrimental changes, including unfavorable alterations in cholesterol profiles, elevated blood pressure, and an accelerated buildup of plaque within blood vessels. These combined factors collectively heighten a woman’s susceptibility to serious cardiovascular events, such as heart attack and stroke. Indeed, CVD is the leading cause of death for women globally, with risk significantly increasing post-menopause.
The research team’s primary motivation stemmed from an interest in thoroughly understanding the long-term impact of hormone therapy on cardiovascular biomarkers, an area that had not been extensively evaluated over prolonged durations in prior research. Most existing studies in the field had predominantly focused on short-term effects, leaving a significant gap in knowledge regarding sustained impacts.
Methodology: A Deep Dive into WHI Data
To address this gap, Nudy’s team embarked on a comprehensive analysis of cardiovascular biomarkers over a six-year period. Their investigation drew upon data from a specific subset of women who had participated in an oral hormone therapy clinical trial that constituted a component of the broader WHI. Participants in this particular trial were randomly allocated into one of two groups: an estrogen-only group or an estrogen-plus-progesterone group. All participants were post-menopausal and ranged in age from 50 to 79 years at the time of their assignment. Blood samples were systematically collected at baseline, and subsequently at one, three, and six years following the initiation of therapy. In total, the researchers meticulously analyzed samples from 2,696 women, representing approximately 10% of the overall participants in the original trial. This substantial sample size and extended follow-up period lend considerable weight to the study’s findings, allowing for robust statistical analysis of long-term trends.
Key Findings: A Mixed but Promising Picture of Biomarker Changes
The research team’s analysis revealed that hormone therapy exerted a generally beneficial influence on a majority of the assessed cardiovascular biomarkers in both the estrogen-only and the estrogen-plus-progesterone groups over the six-year observation period. Specifically, levels of low-density lipoprotein (LDL) cholesterol, often referred to as the "bad" cholesterol due to its role in arterial plaque formation, were notably reduced by approximately 11%. Concurrently, total cholesterol levels and insulin resistance, a precursor to type 2 diabetes and a significant CVD risk factor, also demonstrated decreases in both treatment arms. Conversely, high-density lipoprotein (HDL) cholesterol, commonly known as the "good" cholesterol for its protective role against atherosclerosis, exhibited increases of 13% and 7% in the estrogen-only and estrogen-plus-progesterone groups, respectively. These improvements in lipid profiles and insulin sensitivity are generally indicative of a healthier cardiovascular milieu.
However, the study also noted some less favorable changes: levels of triglycerides, a type of fat in the blood, and coagulation factors, proteins essential for blood clot formation, were observed to increase. This dual effect underscores the complex physiological responses to hormone therapy and highlights the need for a nuanced understanding of its overall impact.
The Surprising Revelation: Lipoprotein(a) Reduction
Perhaps the most compelling and surprising discovery for the research team was the significant reduction in levels of lipoprotein(a) [Lp(a)], a distinct type of cholesterol molecule. Lp(a) levels decreased by an impressive 15% in the estrogen-only group and an even more substantial 20% in the estrogen-plus-progesterone group. Unlike other forms of cholesterol, whose concentrations can be significantly modulated by lifestyle factors such as diet, exercise, and smoking habits, Lp(a) concentrations are predominantly determined by an individual’s genetic makeup. Elevated Lp(a) concentrations are a well-established, independent genetic risk factor associated with a substantially increased risk of heart attack and stroke, particularly at younger ages. Furthermore, high Lp(a) is also linked to an increased risk of aortic stenosis, a serious condition characterized by the calcification and narrowing of the heart’s aortic valve.
"As a cardiologist, this finding is the most interesting aspect of this research," Dr. Nudy commented, highlighting the clinical significance of this particular result. He further explained, "Currently, there are no medications approved by the Food and Drug Administration (FDA) specifically designed to lower lipoprotein(a). Here, we essentially found that oral hormone therapy significantly reduced lipoprotein(a) concentrations over the long-term." This discovery is particularly impactful given the lack of therapeutic options for Lp(a) management and opens new avenues for considering HT in specific patient populations.
Racial and Ethnic Disparities in Lp(a) Reduction
Adding another layer of complexity and intrigue to their findings, the research team examined the study’s outcomes by self-reported racial and ethnic groups. They observed that the decrease in Lp(a) concentration was notably more pronounced among participants with American Indian or Alaska Native ancestry, showing a remarkable 41% reduction, and among those with Asian or Pacific Islander ancestry, where a 38% decrease was noted. Dr. Nudy acknowledged that the precise reasons behind these steeper reductions in specific ancestral groups are not yet clear. However, the team expressed a strong intention to investigate these fascinating disparities further in subsequent research studies, recognizing the potential implications for personalized medicine and health equity.
Understanding the Mechanism: Oral vs. Transdermal Estrogen
Dr. Nudy also provided critical context regarding the specific type of estrogen therapy administered in the clinical trial: conjugated equine estrogens, a commonly prescribed form of oral estrogen therapy. He elucidated that oral hormone therapy, prior to its systemic absorption and therapeutic action, undergoes a process known as first-pass metabolism in the liver. This hepatic processing, while enabling drug activation, can potentially increase inflammatory markers in the body. This mechanism offers a plausible explanation for the observed increases in triglycerides and coagulation factors in the study, as hepatic metabolism can influence lipid synthesis and coagulation cascade components.
In contrast, Nudy pointed out that "There are now other common formulations of estrogen hormone therapy like transdermal estrogen, which is administered through the skin." He elaborated that "Newer studies have found that transdermal estrogen doesn’t increase triglycerides, coagulation factors or inflammatory markers." This distinction is crucial, as it suggests that the mode of delivery for hormone therapy can significantly influence its metabolic profile and potential side effects, allowing for more tailored treatment approaches based on individual patient risk factors.
Clinical Recommendations and Future Directions
For individuals contemplating menopause hormone therapy, Dr. Nudy strongly recommended undergoing a comprehensive cardiovascular disease risk assessment. This recommendation holds true even for those who have no prior history of heart attack or stroke, or who have not been formally diagnosed with cardiovascular disease. Such an assessment provides healthcare providers with invaluable additional information, enabling them to make more informed decisions regarding the most appropriate and safest option for managing menopause symptoms, considering the individual’s overall health profile and specific risk factors.
It is important to reiterate, as Nudy clarified, that "Currently, hormone therapy is not FDA-approved to reduce the risk of coronary artery disease or stroke." This statement emphasizes that while the study’s findings are promising, especially concerning Lp(a), hormone therapy’s primary indication remains the alleviation of menopausal symptoms, and its use for primary CVD prevention is not yet endorsed by regulatory bodies.
The implications of this study are far-reaching. For millions of women entering or navigating menopause, these findings offer a renewed perspective on the potential long-term benefits of HT, particularly in the context of cardiovascular health. The focus on Lp(a) is a game-changer, as it targets a genetic risk factor for which current therapeutic options are severely limited. This could lead to a re-evaluation of HT’s role in women with high Lp(a) levels, potentially positioning it as a unique intervention in specific cases, under careful medical supervision.
Future research will undoubtedly delve deeper into the mechanisms behind the observed racial and ethnic differences in Lp(a) reduction, aiming to uncover genetic or environmental factors that may explain these variances. Further comparative studies between oral and transdermal estrogen formulations are also warranted to fully delineate their respective long-term cardiovascular profiles and to guide personalized treatment decisions. The insights gleaned from Nudy’s study will not only inform clinical practice but also stimulate the development of novel therapies for Lp(a) management and contribute to a more comprehensive understanding of women’s cardiovascular health during and after the menopausal transition.
The distinguished list of other authors contributing to this pivotal paper includes: Aaron Aragaki from the Fred Hutchinson Cancer Center; Peter Schnatz and Xuezhi Jiang from Drexel University College of Medicine; JoAnn Manson from Brigham and Women’s Hospital, Harvard Medical School, and Harvard T.H. Chan School of Public Health; Aladdin Shadyab from the University of California San Diego; Su Yong Jung from the University of California Los Angeles; Lisa Martin from The George Washington University; Robert Wild from the University of Oklahoma Health Sciences Center; Catherine Womack from the University of Tennessee Health Science Center; Charles Mouton from the University of Texas Medical Branch; and Jacques Rossouw, formerly of the National Heart, Lung, and Blood Institute at the National Institutes of Health. This collaborative effort underscores the multi-institutional dedication to advancing knowledge in women’s health. The funding necessary to support this vital work was generously provided by the National Center for Advancing Translational Sciences.
